Blog

T cells

Autolomous and Vineti form strategic partnership to deliver end to end supply chain management solutions for cell and gene therapy sector

Autolomous LTD, the market leading developer of critical manufacturing management systems for cell and gene therapies, and Vineti, a provider of leading digital enterprise platforms for cell and gene therapy supply chains, today announce a non-exclusive collaborative partnership.

Read More
July 10, 2019

Supply chain management readiness, Part 4: quality risk management

Note: this post is the last of a four-part series on supply chain planning for personalized therapies such as cell...

June 12, 2019

ISCT 2019: data elements in the cell therapy value chain

I just got back from speaking at the International Society for Cell Therapy annual meeting, where the topic was next-gen data management....

June 4, 2019

Supply chain management readiness, Part 3: process

(Note: this post is the third part of a four-part series on supply chain planning for personalized therapies such as...

May 30, 2019

When the patient is the product — some key challenges in cell and gene therapies

In personalized therapies — cell therapies, gene therapies, and neoantigen therapies — a patient is not just the recipient of...

May 15, 2019

Supply chain management readiness, Part 2: operational ecosystem

(Note: this post is the second part of a four-part series on supply chain planning for personalized therapies such as...

April 24, 2019

Supply chain management readiness, Part 1: strategy

There are many critical decisions to be made when moving a large-molecule biologic out of the lab into human trials....